Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Cholangiocarcinoma

sorafenib has been researched along with Cholangiocarcinoma in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (21.88)29.6817
2010's19 (59.38)24.3611
2020's6 (18.75)2.80

Authors

AuthorsStudies
Chen, Q; Deng, CX; Feng, Y; Lei, JH; Lu, L; Lyu, X; Quan, Y; Sun, H; Wang, H; Xu, J; Xu, X; Zeng, J; Zhao, M1
Fey, D; Malik, IA; Rajput, M; Salehzadeh, N; von Arnim, CAF; Werner, R; Wilting, J1
Christ, B; Koch, M; Leskova, M; Lieshout, R; Lissek, SM; Nickel, S; Pampaloni, F; van der Laan, LJW; Verstegen, MMA1
Balcar, L; Finkelmeier, F; Himmelsbach, V; Mahyera, A; Mozayani, B; Pinter, M; Pomej, K; Scheiner, B; Shmanko, K; Trauner, M; Vogel, A; Weinmann, A; Welland, S1
Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B1
Ye, B; Zhang, J; Zheng, Y1
Kitazawa, M; Kobayashi, A; Matsumura, T; Miyagawa, SI; Motoyama, H; Notake, T; Shimizu, A; Takeoka, M; Yokoi, K; Yokoyama, T1
Futsukaichi, Y; Kobayashi, S; Minemura, M; Nagata, K; Tajiri, K; Takahara, T; Yasuda, I; Yasumura, S1
Al-Abdulla, R; Alonso-Peña, M; Andersen, JB; Asensio, M; Avila, MA; Banales, JM; Briz, O; Del Carmen, S; Lozano, E; Macias, RIR; Marin, JJG; Martinez-Chantar, ML; Monte, MJ; Munoz-Garrido, P; O'Rourke, CJ; Sanchez-Vicente, L; Satriano, L1
Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J1
Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM1
Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P1
Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH1
Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB1
Seino, S; Tsuchiya, A; Watanabe, M1
Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M1
Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X1
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z1
Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T1
Foreman, B; Hicks, MD; LaRocca, RV; Mull, L1
Barreiros, AP; Galle, PR; Krupp, M; Maass, T; Strand, S; Teufel, A; Thieringer, F; Wang, C; Wörns, MA1
Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW1
Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S1
Huang, FK; Shi, Z1
Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F1
Baba, N; Hyodo, I; Ishige, K; Matsuda, S; Nakanuma, Y; Onodera, M; Onuki, K; Shoda, J; Sugiyama, H; Takeuchi, K; Ueda, T; Yamamoto, M; Yamato, M1
Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ1
Faris, JE; Zhu, AX1
Brendel, E; Christensen, O; Grubert, M; Haase, CG; Hilger, RA; Kupsch, P; Passage, K; Richly, H; Schwartz, B; Strumberg, D; Voigtmann, R1
Adusumilli, J; Baxter, DL; El-Khoueiry, A; Govindarajan, R; Harik, SI1
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D2

Reviews

2 review(s) available for sorafenib and Cholangiocarcinoma

ArticleYear
Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature.
    Clinical journal of gastroenterology, 2019, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Remission Induction; Sorafenib

2019
Targeted therapy for biliary tract cancers.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2012

Trials

7 trial(s) available for sorafenib and Cholangiocarcinoma

ArticleYear
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Everolimus; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib

2023
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome

2013
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A

2014
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Oncotarget, 2017, Mar-07, Volume: 8, Issue:10

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administration Schedule; Exanthema; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome

2017
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib

2010
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Disease-Free Survival; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2012
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
    International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:11

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Area Under Curve; Benzenesulfonates; Cholangiocarcinoma; Doxorubicin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2004

Other Studies

23 other study(ies) available for sorafenib and Cholangiocarcinoma

ArticleYear
Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice.
    International journal of biological sciences, 2021, Volume: 17, Issue:15

    Topics: Animals; Antibodies; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; CRISPR-Cas Systems; Cullin Proteins; Gene Expression Regulation; Gene Knockdown Techniques; Liver; Liver Neoplasms; Mice; Mutation; Programmed Cell Death 1 Receptor; PTEN Phosphohydrolase; Smad4 Protein; Sorafenib; Tumor Microenvironment

2021
Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer.
    BMC cancer, 2022, Nov-19, Volume: 22, Issue:1

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Dasatinib; Hepatoblastoma; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; Sorafenib

2022
Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
    Cells, 2022, 11-15, Volume: 11, Issue:22

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans; Ki-67 Antigen; Organoids; Sorafenib

2022
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
    ESMO open, 2023, Volume: 8, Issue:1

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib

2023
miR-138 mediates sorafenib-induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells.
    Clinical and experimental pharmacology & physiology, 2020, Volume: 47, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Cell Survival; Cholangiocarcinoma; Female; Humans; Male; MicroRNAs; Middle Aged; Prognosis; Sorafenib

2020
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases

2018
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:4

    Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; DNA Methylation; Down-Regulation; Drug Resistance; Genetic Therapy; Humans; Immunoblotting; Male; Octamer Transcription Factor-1; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Statistics, Nonparametric

2019
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholangiocarcinoma; Female; Humans; In Vitro Techniques; Liver Neoplasms; Molecular Sequence Data; Niacinamide; Oocytes; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib; Treatment Outcome; Xenopus laevis

2013
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
    International journal of nanomedicine, 2013, Volume: 8

    Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Evaluation, Preclinical; Drug-Eluting Stents; Human Umbilical Vein Endothelial Cells; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Xenograft Model Antitumor Assays

2013
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:6

    Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib

2013
A rare primary liver tumor that responded to sorafenib.
    Gastroenterology, 2014, Volume: 147, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib

2014
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
    Journal of vascular and interventional radiology : JVIR, 2015, Volume: 26, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes

2015
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Oncotarget, 2016, Apr-12, Volume: 7, Issue:15

    Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured

2016
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
    Anti-cancer drugs, 2016, Volume: 27, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays

2016
Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    Journal of gastrointestinal cancer, 2007, Volume: 38, Issue:2-4

    Topics: Adult; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; Humans; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome

2007
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
    Journal of hepatology, 2009, Volume: 50, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biological Evolution; Cholangiocarcinoma; Computational Biology; Databases, Genetic; Extracellular Space; Humans; MAP Kinase Signaling System; Mice; Multigene Family; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Sorafenib; Systems Biology

2009
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:6

    Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine

2009
[Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response Relationship, Drug; Down-Regulation; Humans; Lymphangiogenesis; Lymphatic Vessels; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Random Allocation; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3

2010
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:1-2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome

2011
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Journal of gastroenterology, 2011, Volume: 46, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays

2011
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cholangiocarcinoma; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Hypertensive Encephalopathy; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Syndrome

2006
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Biochemical pharmacology, 2007, May-01, Volume: 73, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, IGF Type 1; Sorafenib; Tumor Cells, Cultured; Tyrphostins

2007
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    World journal of gastroenterology, 2007, Sep-07, Volume: 13, Issue:33

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib

2007